Buscar
Prothena Corporation PLC
PRTAAñadir a la lista de seguimiento
8.320USD
-0.360-4.15%
Cierre 09-24 16:00（ET）
435.55MCap. mercado
PérdidaP/E TTM
Acerca de Prothena Corporation PLC Compañía
Prothena Corporation plc is an Ireland-based late-stage clinical biotechnology company. The Company is engaged in protein dysregulation and a pipeline of investigational therapeutics for rare peripheral amyloid diseases. The Company is advancing a pipeline of therapeutic candidates for a range of indications and targets to integrate scientific insights around neurological dysfunction and the biology of misfolded proteins. The Company’s pipeline includes both wholly owned and partnered programs being developed for the potential treatment of diseases, including AL amyloidosis, ATTR amyloidosis, Alzheimer’s disease, Parkinson’s disease and a range of other neurodegenerative diseases. Its clinical programs include birtamimab for the potential treatment of AL amyloidosis, prasinezumab for the potential treatment of Parkinson’s disease, NNC6019/PRX004 for the potential treatment of ATTR amyloidosis, and PRX005 and PRX012 for the potential treatment of Alzheimer’s disease.
Perfil de Prothena Corporation PLC
Símbolo de cotizaciónPRTA
Nombre de la empresaProthena Corporation PLC
Fecha de salida a bolsaDec 21, 2012
Director ejecutivoKinney (Gene G)
Número de empleados163
Tipo de seguridadOrdinary Share
Fin del año fiscalDec 21
Dirección77 Sir John Rogerson's Quay, Block C
CiudadDUBLIN
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísIreland
Código postalD02 VK60
Teléfono35312362500
Sitio Webhttps://www.prothena.com/
Símbolo de cotizaciónPRTA
Fecha de salida a bolsaDec 21, 2012
Director ejecutivoKinney (Gene G)
Ejecutivos de Prothena Corporation PLC
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Mr. Michael Isaacs
Mr. Michael Isaacs
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
35.74K
-36.59%
Dr. Dennis J. Selkoe, M.D.
Dr. Dennis J. Selkoe, M.D.
Independent Director
Independent Director
4.21K
--
Ver más
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Mr. Brandon S. Smith
Mr. Brandon S. Smith
Chief Operating Officer
Chief Operating Officer
130.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Dr. Wagner M. Zago, Ph.D.
Dr. Wagner M. Zago, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
85.00K
--
Preguntas frecuentes
¿Quiénes son los cinco principales accionistas de Prothena Corporation PLC?
Los cinco principales accionistas de Prothena Corporation PLC son: Mr. Brandon S. Smith
¿Cuántas instituciones poseen acciones de Prothena Corporation PLC (PRTA)?
A fecha de 2026Q1, 436 instituciones poseen acciones de Prothena Corporation PLC, con un valor de mercado combinado de aproximadamente 50.39M, lo que representa el 96.24% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -14521914.00.